MAPK/ERK Signaling Pathway: RAS–RAF–MEK–ERK Cascade Regulation, Cellular Functional Outputs, and Research Tool Applications
MAPK/ERK Signaling Pathway: RAS–RAF–MEK–ERK Cascade Regulation, Cellular Functional Outputs, and Research Tool Applications
1. Overview of the MAPK/ERK Pathway
After cells are stimulated by growth factors such as EGF, FGF, and PDGF, why can ERK phosphorylation occur within minutes, while cellular proliferation, differentiation, migration, or survival states change over hours to days? In tumor cells, why can a single KRAS or BRAF mutation continuously drive cell proliferation and drug tolerance? The core of these questions points to the same classical signaling axis: the MAPK/ERK signaling pathway.
MAPK stands for mitogen-activated protein kinase; ERK stands for extracellular signal-regulated kinase. In a broad sense, the MAPK family includes multiple branches, such as ERK, JNK, p38, and ERK5, which are involved in growth factor responses, stress responses, inflammatory responses, and developmental regulation, respectively. This article focuses on the classical ERK1/2 pathway, namely:
RAS → RAF → MEK1/2 → ERK1/2
ERK1 is also known as MAPK3, and ERK2 is also known as MAPK1. The classical MAPK/ERK pathway is usually activated by growth factors, receptor tyrosine kinases, cell adhesion signals, or oncogenic mutations, ultimately affecting biological processes such as cell proliferation, differentiation, migration, survival, senescence, and drug tolerance.
The core of this pathway lies in how cells convert the same kinase cascade into different cell fates through the intensity, duration, subcellular localization, substrate selection, and feedback regulation of ERK activation.
Core Mechanism Diagram of the MAPK/ERK Signaling Pathway: This diagram illustrates how the MAPK/ERK signaling pathway is activated, starting from extracellular stimuli, membrane receptor inputs, and the RAS molecular switch, progressing through the core RAF–MEK–ERK cascade. It also shows the roles of p-ERK1/2 in nuclear transcriptional regulation, cytoplasmic functional outputs, ERK dynamic encoding, and negative feedback/scaffold-mediated regulation.
The basic logic of the MAPK/ERK pathway is as follows:
Growth factors / Adhesion signals / GPCR signals / Oncogenic mutations
↓
Upstream receptors or signaling complexes such as RTKs, GPCRs, and integrins
↓
GRB2–SOS complex
↓
RAS-GDP → RAS-GTP
↓
RAF → MEK1/2 → ERK1/2
↓
Transcription factors, cell-cycle proteins, translational regulators, and migration- and survival-related substrates
↓
Proliferation, differentiation, migration, survival, senescence, and drug resistance
2. How Upstream Signals Enter the MAPK/ERK Pathway
The MAPK/ERK pathway can receive multiple upstream inputs. The classical route is the RTK–GRB2–SOS–RAS axis, but GPCRs, integrins, cytokine receptors, and certain stress stimuli can also affect ERK activity through different mechanisms.
2.1 RTK–GRB2–SOS–RAS Is the Classical Entry Point
RTK stands for receptor tyrosine kinase. RTKs such as EGFR, FGFR, PDGFR, VEGFR, MET, and TRK can activate the MAPK/ERK pathway in different cell types.
Taking EGF–EGFR as an example, EGF stands for epidermal growth factor, and EGFR stands for epidermal growth factor receptor. After EGF binds to EGFR, EGFR undergoes dimerization and autophosphorylation of intracellular tyrosine residues. These phosphorylated tyrosine sites can serve as docking sites for adaptor proteins and recruit GRB2.
GRB2 stands for growth factor receptor-bound protein 2. GRB2 recognizes phosphorylated tyrosine residues on the receptor through its SH2 domain and recruits SOS through its SH3 domains. SOS stands for son of sevenless and is a guanine nucleotide exchange factor, or GEF. SOS promotes the release of GDP from RAS and the binding of GTP, thereby switching RAS into its active state.
EGF → EGFR dimerization and tyrosine autophosphorylation → GRB2 recruits SOS → SOS promotes the conversion of RAS-GDP to RAS-GTP → RAS-GTP recruits and activates RAF
The key point in this process is that phosphorylated receptor sites localize the GRB2–SOS complex near the plasma membrane, allowing SOS to access membrane-localized RAS and thereby increasing the efficiency of RAS-GTP formation.
2.2 How GPCRs, Integrins, and Other Stimuli Connect to ERK
GPCR stands for G protein-coupled receptor. Some GPCRs can connect to the ERK pathway through G protein subunits, β-arrestin, Src family kinases, or RTK transactivation mechanisms. Certain hormone, neurotransmitter, and chemokine signals can activate ERK through GPCRs, thereby influencing secretion, migration, proliferation, or neuronal plasticity.
Integrins sense the extracellular matrix and the cell adhesion state. Integrins can connect to the RAS–ERK axis through molecules such as FAK, Src, Shc, and GRB2, allowing cells to convert “whether they are attached to an appropriate matrix” into proliferation, migration, or survival signals.
Cytokines, oxidative stress, ultraviolet radiation, DNA damage, and other stimuli may also affect ERK. However, these stimuli usually affect JNK, p38, PI3K/AKT, NF-κB, and other pathways at the same time. Therefore, in stress or inflammation models, increased p-ERK cannot be directly equated with classical growth factor-type RTK–RAS activation.
3. The RAS–RAF–MEK–ERK Cascade
The core of the MAPK/ERK pathway is the RAS–RAF–MEK–ERK cascade. RAS acts as a small GTPase switch that receives upstream inputs, while RAF, MEK, and ERK transmit and amplify signals through sequential phosphorylation.
Level | Representative molecules | Core function | Common detection or research indicators |
Input layer | RTKs, GPCRs, integrins | Sense growth factors, adhesion, chemokines, or environmental stimuli | p-EGFR, p-FGFR, p-MET, validation using receptor inhibitors |
Switch layer | RAS-GDP/RAS-GTP | Convert receptor signals into a GTPase activation state recognizable by RAF | RAS-GTP pull-down assay, RAS mutation detection |
MAP3K layer | ARAF, BRAF, CRAF/RAF1 | Receive RAS-GTP signals and activate MEK | Phosphorylation of specific RAF sites/isoforms, RAF mutation/dimerization status, RAF inhibitor sensitivity, combined with p-MEK/p-ERK assessment |
MAP2K layer | MEK1/2 | ERK1/2 are the main classical substrates; responsible for dual-site phosphorylation of ERK | p-MEK1/2, MEK inhibitors |
MAPK layer | ERK1/2 | Phosphorylate cytoplasmic and nuclear substrates to generate functional outputs | p-ERK1/2, nuclear translocation, p-RSK, p-ELK1 |
Output layer | ELK1, RSK, Cyclin D1, BIM, MCL-1, paxillin, MLCK, etc. | Regulate transcription, cell cycle, translation, migration, and survival | Western blot, immunofluorescence, functional assays |
3.1 RAS: A Molecular Switch Controlled by the GDP/GTP State
RAS is a family of small GTPase proteins, including KRAS, NRAS, and HRAS. The activity of RAS depends on its bound nucleotide state.
GEFs, or guanine nucleotide exchange factors, promote the release of bound GDP from RAS, allowing RAS to bind the relatively abundant intracellular GTP and form active RAS-GTP. SOS is a classical RAS-GEF. GAPs, or GTPase-activating proteins, promote the hydrolysis of RAS-GTP into RAS-GDP, switching RAS from the active state back to the inactive state. NF1 is an important RAS-GAP.
The GDP/GTP conversion of RAS can be represented as follows:
Nucleotide exchange:
RAS·GDP + GTP ⇌ RAS·GTP + GDP
↑
GEF/SOS promotes GDP release and GTP binding
GTP hydrolysis:
RAS·GTP + H₂O → RAS·GDP + Pi
↑
GAP/NF1 accelerates the hydrolysis reaction
Here, RAS·GDP represents the GDP-bound state of RAS, which is usually inactive; RAS·GTP represents the GTP-bound state of RAS, which can bind and recruit downstream effector proteins such as RAF and initiate the RAF–MEK–ERK cascade.
Oncogenic RAS mutations commonly occur at key sites in KRAS, NRAS, or HRAS. These mutations can weaken the intrinsic GTP hydrolysis activity of RAS or reduce its sensitivity to GAP-mediated inactivation, causing RAS to remain in the GTP-bound state for a longer period. Persistent RAS-GTP can enhance RAF recruitment and activation, thereby driving sustained phosphorylation of MEK1/2 and ERK1/2 and promoting abnormal proliferation, survival, and tumor progression.
3.2 RAF: The MAP3K Connecting RAS to MEK
RAF belongs to the MAP3K family, meaning MAP kinase kinase kinase. The RAF family includes ARAF, BRAF, and CRAF/RAF1.
In the resting state, RAF is relatively autoinhibited. After RAS-GTP recruits RAF to the plasma membrane, it can promote RAF membrane localization, conformational changes, regulatory phosphorylation, and dimerization, ultimately activating RAF kinase activity. Activated RAF then phosphorylates MEK1/2.
RAS-GTP → RAF membrane recruitment, conformational change, and dimerization → RAF kinase activation → MEK1/2 phosphorylation
BRAF V600E is one of the most classical activating RAF mutations in tumors. It can cause abnormally enhanced BRAF kinase activity and continuously drive MEK–ERK output. However, RAF mutations are complex. Different mutations vary in their requirements for RAF dimerization, upstream RAS dependence, and inhibitor sensitivity. Therefore, not all RAF mutations should be considered equivalent to BRAF V600E.
3.3 MEK1/2: Highly Specific Upstream Kinases of ERK
MEK1/2 stands for MAPK/ERK kinase 1/2 and is also known as MAP2K1/2. The main classical substrates of MEK1/2 are ERK1/2, and its substrate specificity is much higher than that of most kinases. After RAF activates MEK, MEK1/2 phosphorylates the TEY motif of ERK1/2 at two sites, thereby activating ERK.
RAF → p-MEK1/2
p-MEK1/2 → p-ERK1/2
In experiments, p-ERK1/2 antibodies are commonly used to detect the dual-phosphorylated active state of ERK1/2. It should be noted that MEK inhibitors reducing p-ERK can indicate that ERK activation depends on MEK, but this alone cannot prove that a given cellular phenotype is determined only by the ERK pathway. Downstream substrates, functional phenotypes, and genetic validation are still required.
3.4 ERK1/2: From Kinase Activation to Functional Output
ERK1/2 are the core execution nodes of the classical MAPK/ERK pathway. After MEK activates ERK, ERK can phosphorylate cytoplasmic substrates and can also translocate into the nucleus to regulate transcription factors. ERK has a broad substrate range, involving transcription, cell cycle, translation, metabolism, cytoskeleton organization, migration, and apoptotic sensitivity.
4. How ERK Regulates Cellular Functions
After ERK is activated, it does not directly produce one fixed outcome. Instead, it changes cellular states through different substrate modules. To understand ERK output, its effects need to be divided into several functional layers.
4.1 Transcription Factor Module: Converting Transient Kinase Signals into Gene Expression
After activation, ERK can enter the nucleus and phosphorylate transcription-related factors such as ELK1, ETS family proteins, c-FOS, and c-MYC, thereby inducing immediate early gene expression.
After ELK1 is phosphorylated by ERK, it can promote c-FOS expression. c-FOS and c-JUN can together form the AP-1 transcription factor complex, regulating genes associated with proliferation, differentiation, and migration. c-MYC participates in cell growth, metabolism, and cell-cycle progression.
p-ERK nuclear entry → activation of transcriptional regulators such as ELK1, c-FOS, and c-MYC → immediate early gene expression → changes in transcriptional programs related to cell cycle, differentiation, or migration
If an experiment only observes increased p-ERK without detecting downstream readouts such as p-ELK1, c-FOS, c-MYC, or Cyclin D1, it can only show that ERK has been activated; it cannot show that complete transcriptional output has occurred.
4.2 Cell-Cycle Module: Promoting the G1/S Transition
One important effect of ERK on cell proliferation is the promotion of the transition from G1 phase to S phase. ERK can increase Cyclin D1 levels through transcriptional regulation and regulation of protein stability. After Cyclin D1 forms a complex with CDK4/6, it promotes phosphorylation of RB protein and releases E2F transcription factors, thereby initiating the expression of genes related to DNA synthesis.
ERK activation → Cyclin D1 upregulation → enhanced CDK4/6 activity → RB phosphorylation → E2F release → progression of the G1/S transition
It should be noted that ERK promoting cell-cycle entry does not necessarily mean effective proliferation will occur. If cells simultaneously experience DNA damage, nutrient deficiency, severe stress, or activation of tumor suppressor pathways, ERK signaling may fail to translate into proliferation and may even participate in senescence or cell death programs.
4.3 Translation and Metabolism Module: Supporting Cell Growth
ERK can regulate protein translation through RSK and MNK. RSK stands for ribosomal S6 kinase; MNK stands for MAPK-interacting kinase. These downstream kinases can influence ribosome-associated proteins, translation initiation factors, and mRNA translation efficiency, allowing cells to acquire sufficient protein synthesis capacity during proliferation or differentiation.
The transcriptional output of ERK requires coordination with the protein synthesis system before cells can complete growth, cell-cycle entry, or differentiation programs. If ERK induces only partial transcriptional changes while translation, metabolism, or nutrient supply remains insufficient, the cellular functional output may be incomplete.
4.4 Survival and Apoptosis Module: Regulating the Threshold for Cell Death
ERK can regulate multiple apoptosis-related proteins. For example, the ERK/RSK axis can influence pro-apoptotic proteins such as BIM and BAD, and can also enhance cell survival by regulating MCL-1 stability. MCL-1 is an anti-apoptotic member of the BCL-2 family, while BIM is a pro-apoptotic BH3-only protein.
In tumor cells, sustained ERK activation often increases tolerance to apoptotic stimuli, allowing cells to survive under growth factor deprivation, drug pressure, or metabolic stress. However, in specific contexts, excessively strong or sustained ERK signaling can also trigger senescence or cell death. The effect of ERK on survival and apoptosis must be judged in combination with cell type, stimulus intensity, duration, and the status of downstream proteins.
4.5 Migration and Cytoskeleton Module: Changing Cell Morphology and Motility
ERK can influence focal adhesions, the actin cytoskeleton, and cell migration through migration- and cytoskeleton-related nodes such as paxillin and MLCK, as well as through crosstalk with FAK/Src–integrin adhesion signaling. FAK stands for focal adhesion kinase; paxillin is a focal adhesion scaffold protein; MLCK stands for myosin light-chain kinase. In tumor invasion, fibroblast migration, endothelial cell responses, and tissue repair, ERK not only regulates whether cells enter a proliferative state, but also whether cells change their morphology, adhesion, and migratory capacity.
5. How ERK Signaling Encodes Different Cell Fates
The same MAPK/ERK pathway can produce different outcomes in different cells, including proliferation, differentiation, migration, survival, senescence, and even death. This is because ERK signaling has dynamic encoding characteristics. ERK output mainly depends on five factors: activation duration, activation intensity, subcellular localization, substrate accessibility, and feedback regulation.
5.1 Temporal Encoding: Transient and Sustained Activation Produce Different Outputs
Transient ERK activation usually induces transient expression of immediate early genes; sustained or repeated ERK activation is more likely to maintain transcription factor activity, protein expression, and cell-cycle- or differentiation-related programs. It should be noted that the relationship between ERK dynamics and cell fate is dependent on cell type and stimulation context.
A classical model comes from PC12 cells. EGF often induces relatively transient ERK activation and is more associated with proliferative responses; NGF can induce more sustained ERK activation and promote neuron-like differentiation.
ERK dynamic feature | Common functional tendency | Mechanistic explanation |
Transient activation | Transient expression of immediate early genes and short-term responses | The signal duration is relatively short and is usually insufficient to maintain long-term transcriptional programs |
Sustained activation | Sustained transcriptional output, G1/S progression, differentiation, senescence, or long-term adaptation | Transcription factors remain phosphorylated, and protein expression programs are maintained |
Pulsatile activation | Changes in cell-fate probability at the single-cell level | Different cells receive signals with different frequencies and durations |
5.2 Spatial Encoding: Nuclear ERK and Cytoplasmic ERK Have Different Functions
ERK has different substrates in the cytoplasm and the nucleus. Nuclear ERK mainly regulates transcription factors and gene expression, while cytoplasmic ERK more often regulates RSK, MNK, cytoskeletal proteins, migration, and survival-related proteins.
Therefore, even when increased p-ERK is detected, it is still necessary to further determine where p-ERK is located. If ERK is mainly activated in the cytoplasm, it may not necessarily produce strong transcriptional output; if ERK persistently enters the nucleus, it is more likely to drive gene expression and cell-fate changes.
5.3 Intensity Encoding: Different Substrates Have Different Activation Thresholds
Different ERK substrates have different sensitivities to ERK activity. Some substrates can be phosphorylated when ERK activation is at a low level, whereas others require higher intensity or longer duration of ERK activation. Strong signals may activate more downstream modules, while weak signals may produce only local regulation.
5.4 Substrate Accessibility: The Same ERK Signal Produces Different Results in Different Cells
Different cells express different ERK substrates. Chromatin accessibility, transcription factor composition, scaffold protein distribution, and cell-cycle state also differ. Therefore, the same ERK activation can produce different outcomes in epithelial cells, neuronal cells, immune cells, and tumor cells.
5.5 Single-Cell Dynamics: Population Averages May Mask Real Differences
The p-ERK detected by Western blot represents an average result across a cell population. In reality, ERK in individual cells can display pulsatile, oscillatory, or sustained activation. Two samples with similar overall p-ERK levels may differ substantially: in one sample, most cells may show moderate activation, while in the other, only a small number of cells may show strong activation. These two patterns may correspond to different cell fates. Therefore, when cell-fate heterogeneity needs to be explained, immunofluorescence, live-cell ERK reporter systems, and single-cell analysis are more informative than Western blot alone.
6. Negative Feedback and Signal Termination
The MAPK/ERK pathway is not a one-way cascade that simply turns on. It has strong negative feedback regulation, which can limit signal intensity and duration and prevent excessive ERK activation from causing abnormal proliferation or cellular damage.
6.1 DUSP/MKP Dephosphorylates ERK to Turn Off the Signal
DUSP stands for dual-specificity phosphatase and is also known as MKP, or MAPK phosphatase. DUSPs can remove phosphate groups from ERK, thereby inactivating ERK.
p-ERK
↓ DUSP/MKP
ERK dephosphorylation
↓
Reduced ERK activity
DUSPs are a representative class of molecules in ERK negative feedback. After ERK is activated, it can induce the expression of certain DUSPs, which in turn reduce ERK activity, forming a self-limiting regulatory loop.
Different DUSPs have certain subcellular localization patterns and substrate preferences. For example, DUSP5 preferentially regulates ERK in the nucleus, whereas DUSP6/MKP-3 preferentially regulates ERK in the cytoplasm. Therefore, DUSP feedback can also affect the spatial distribution of ERK signaling.
6.2 The SPRY Family Restricts Upstream RTK–RAS Input
SPRY refers to members of the Sprouty protein family. The SPRY family can negatively regulate RTK–RAS–ERK input, although the exact site of action depends on receptor type, cellular context, and stimulation conditions. It can limit excessive entry of growth factor signals into the ERK cascade. In certain tumor or drug-treatment contexts, if negative feedback is weakened or relieved, upstream RTK signals may become compensatorily enhanced. This is also one important reason why pathway reactivation can occur after RAF, MEK, or ERK inhibition.
6.3 ERK Provides Feedback Inhibition to SOS and RAF
ERK not only activates downstream signaling but can also phosphorylate upstream regulatory factors, such as SOS or RAF, thereby weakening sustained activation of RAS or RAF.
ERK activation → feedback regulation of SOS, RAF, or receptor signaling complexes → reduced sustained upstream input → limitation of excessive ERK activation
This feedback gives the MAPK/ERK pathway a self-limiting capacity. Precisely because feedback exists, after MEK or ERK is pharmacologically inhibited, upstream RTKs, RAS, or parallel pathways may become enhanced due to feedback relief, leading to partial signal recovery or diversion into other pathways.
6.4 KSR and Other Scaffold Proteins Influence Signaling Efficiency and Spatial Organization
KSR stands for kinase suppressor of Ras. Although its name contains the word “suppressor,” KSR often functions as a scaffold protein in the ERK pathway. KSR can organize RAF, MEK, and ERK into signaling complexes, increase signal transmission efficiency, and influence the spatial distribution of signals inside the cell.
7. Crosstalk with Other Pathways
The MAPK/ERK pathway rarely acts alone. Most cellular stimuli activate multiple signaling pathways at the same time, so studies of ERK need to consider parallel and crosstalk regulation.
7.1 PI3K/AKT and ERK Are Activated in Parallel
PI3K stands for phosphoinositide 3-kinase; AKT is a serine/threonine protein kinase. After RTK activation, the RAS–ERK and PI3K–AKT pathways are often initiated simultaneously.
In general, ERK is more associated with proliferation, differentiation, migration, and transcriptional program regulation, while AKT is more associated with survival, metabolism, anti-apoptosis, and nutrient sensing. However, the two pathways are not completely separate. Cell proliferation often requires ERK to drive the cell cycle and AKT to provide survival and metabolic support.
Therefore, if a growth factor promotes cell proliferation while both p-ERK and p-AKT increase, and ERK inhibition only partially reduces proliferation, this cannot demonstrate that the entire effect is mediated by ERK.
7.2 Differences Between JNK/p38 and ERK
JNK stands for c-Jun N-terminal kinase; p38 is another stress-related MAPK. They belong to the MAPK family together with ERK, but their main upstream stimuli and biological outputs differ.
MAPK branch | Typical stimuli | Main outputs |
ERK1/2 | Growth factors, RTKs, RAS/RAF activation, adhesion signals | Proliferation, differentiation, migration, survival |
JNK | Inflammatory factors, stress, DNA damage, cellular pressure | AP-1 activation, apoptosis, inflammation, and stress responses |
p38 | Inflammation, osmotic stress, oxidative stress, cellular stress | Inflammatory factor expression, differentiation, stress adaptation |
7.3 ERK Crosstalk with Cell-Cycle, Senescence, and Apoptosis Pathways
ERK can promote cell-cycle entry through the Cyclin D1–CDK4/6–RB–E2F axis and can also influence the threshold for apoptosis by regulating proteins such as BIM, MCL-1, and BAD.
When RAS–ERK signaling is excessively strong or prolonged, cells may activate tumor suppressor mechanisms such as p53, p16INK4a, and p21, entering oncogene-induced senescence. This explains an apparently contradictory phenomenon: ERK can promote proliferation, but in specific cellular contexts, it may also participate in senescence.
8. MAPK/ERK and Disease
The MAPK/ERK pathway is involved in many diseases, among which cancer is an important and extensively studied area.
8.1 Cancer: Sustained ERK Output Drives Proliferation and Drug Resistance
Abnormal activation of the MAPK/ERK pathway occurs in many tumors. Common mechanisms include RTK amplification or mutation, RAS mutation, BRAF mutation, NF1 loss, and abnormal feedback regulation.
Abnormality type | Mechanistic consequence |
RTK amplification or overexpression | Enhanced upstream input, making RAS–ERK easier to activate |
KRAS, NRAS, or HRAS mutation | Prolonged maintenance of the RAS-GTP state and persistent RAF recruitment |
BRAF V600E | Sustained RAF kinase activation that drives MEK–ERK output |
NF1 loss | Impaired RAS-GTP hydrolysis and enhanced RAS signaling |
DUSP dysregulation | Impaired ERK dephosphorylation and abnormal signal termination |
Sustained ERK activation in tumors can have several consequences: it promotes the expression of cell-cycle-related genes such as Cyclin D1 and enhances cell proliferation; it regulates molecules such as MCL-1 and BIM to raise the apoptotic threshold; it enhances migration and invasion through migration-related mechanisms such as paxillin and MMPs, as well as through crosstalk with FAK/Src adhesion signaling; and it promotes targeted therapy tolerance through feedback remodeling and activation of parallel pathways.
Therapeutic drugs targeting this pathway include BRAF inhibitors, MEK inhibitors, ERK inhibitors, and certain KRAS G12C inhibitors. However, common limitations in cancer therapy include pathway reactivation, feedback relief, changes in RAF dimerization, compensatory RTK activation, and enhancement of parallel pathways such as PI3K/AKT.
8.2 RASopathies: Germline Mutations Cause Developmental Abnormalities
RASopathies are a group of developmental syndromes caused by germline mutations in genes related to the RAS–MAPK pathway, including Noonan syndrome and cardio-facio-cutaneous syndrome. Unlike strong somatic oncogenic mutations in tumors, RASopathies usually involve abnormal regulation or moderate enhancement of pathway activity, affecting development, cardiovascular formation, facial features, and growth processes.
8.3 Nervous System, Cardiovascular, and Inflammation-Related Diseases
In the nervous system, ERK participates in synaptic plasticity, learning and memory, and neuronal differentiation. Abnormal ERK signaling may affect neurodevelopment and neuronal function. In the cardiovascular system, ERK participates in cardiac hypertrophy, vascular smooth muscle proliferation, and endothelial responses. Sustained abnormal activation may promote pathological remodeling.
In inflammation and immunity, ERK can participate in immune cell activation, cytokine expression, and macrophage function. However, inflammatory models usually involve multiple pathways, including NF-κB, JNK, p38, and STAT. Therefore, inflammatory mechanisms cannot be judged based on p-ERK alone.
9. How to Study the MAPK/ERK Pathway Experimentally
The key to studying the MAPK/ERK pathway is to establish an evidence chain from upstream input to downstream functional phenotype.
9.1 Core Detection Indicators
Level | Common indicators | Description |
Upstream receptors | p-EGFR, p-FGFR, p-MET, p-PDGFR | Determine whether the stimulus is effective and whether the receptor is activated |
RAS switch | RAS-GTP pull-down assay | Determine whether RAS has entered the GTP-bound active state |
Intermediate cascade | Phosphorylation of specific RAF sites/isoforms, p-MEK1/2 | Determine whether the RAF–MEK cascade has been initiated |
Core node | p-ERK1/2 | Determine whether ERK is activated |
Cytoplasmic output | p-RSK, p-MNK, BIM, MCL-1 | Determine whether ERK cytoplasmic substrates are regulated |
Nuclear output | p-ELK1, c-FOS, c-MYC, Cyclin D1 | Determine whether ERK produces transcriptional and cell-cycle outputs |
Functional phenotype | EdU, Ki-67, colony formation, migration, apoptosis, differentiation markers | Determine whether signaling changes are converted into cellular behavioral changes |
9.2 Time Gradients Are Critical in MAPK/ERK Experiments
MAPK/ERK is a dynamic pathway. After stimulation with many growth factors, p-ERK increases rapidly within 5–30 minutes and then declines due to DUSP activity and upstream feedback. If only one time point is measured, the peak may be missed, or transient activation may be mistaken for sustained activation.
Research purpose | Suggested time points |
Acute ERK activation | 0, 5, 10, 15, 30, 60 min |
Signal sustainability | 0, 0.5, 1, 2, 4, 8 h |
Transcriptional output | 1, 2, 4, 8, 24 h |
Proliferation or migration phenotype | 24, 48, 72 h or longer |
9.3 Inhibitors and Genetic Validation Should Be Used Together
Inhibitors can rapidly determine pathway dependence, but they should not be used alone as mechanistic conclusions. More rigorous validation should include:
Stimulus or mutation causes increased p-ERK
↓
ERK downstream substrates or transcriptional output changes
↓
Inhibitors block both signaling and phenotype
↓
siRNA, shRNA, or CRISPR validates key nodes
↓
Overexpression or rescue experiments restore signaling or phenotype
Here, siRNA stands for small interfering RNA; shRNA stands for short hairpin RNA; CRISPR stands for clustered regularly interspaced short palindromic repeats and is commonly used for gene knockout or gene editing.
9.4 Common Experimental Pitfalls
Pitfall | Correct approach |
Detecting p-ERK at only one time point | Perform a time-course analysis to distinguish transient activation from sustained activation |
Interpreting increased p-ERK as cell proliferation | Combine with functional indicators such as Cyclin D1, EdU, Ki-67, and colony formation |
Assuming that an effective MEK inhibitor means only the ERK pathway is involved | Simultaneously examine parallel pathways such as PI3K/AKT and JNK/p38 |
Assuming that unchanged total ERK means no pathway change | ERK activation is mainly evaluated by dual-phosphorylated p-ERK and substrate output |
Equating inhibitor results with target conclusions | Genetic perturbation and rescue experiments are required |
Looking only at Western blot | Link the signal to cellular phenotypes such as proliferation, migration, apoptosis, or differentiation |
10. Representative Research Tools and Their Use Logic
When studying the MAPK/ERK pathway, tool selection should be centered on the experimental question. The key is to determine where the signal comes from, which level it depends on, and whether it ultimately changes the functional phenotype.
Research question | Common tools or strategies | Main detection indicators | Interpretation logic |
Does ERK activation come from EGFR or another RTK? | EGFR inhibitors such as gefitinib, erlotinib, and afatinib; or corresponding RTK inhibitors | p-RTK, p-MEK, p-ERK, p-RSK | If p-RTK decreases together with p-MEK and p-ERK, the RTK is an important input source |
Does ERK activation depend on the RAF–MEK axis? | RAF inhibitors and MEK inhibitors, such as vemurafenib, dabrafenib, U0126, and trametinib | p-MEK, p-ERK, p-RSK, p-ELK1 | A decrease in p-ERK after MEK inhibition suggests involvement of the classical MEK–ERK axis; RAF inhibitor results must be interpreted according to RAS/RAF background |
Is the phenotype truly dependent on ERK activity? | ERK inhibitors such as SCH772984 and ulixertinib; ERK1/2 knockdown or knockout | p-ERK substrates, EdU, colony formation, migration, apoptosis | If ERK inhibition blocks both downstream substrates and functional phenotypes, ERK dependence is supported |
Is there RAS mutation dependence? | KRAS G12C inhibitors such as sotorasib and adagrasib; RAS-GTP detection | RAS-GTP, p-MEK, p-ERK, cell viability | KRAS G12C inhibitors apply only to KRAS G12C models and not to all RAS mutations |
Can positive stimulation establish an ERK activation model? | EGF, FGF, PDGF, NGF, etc. | p-ERK time curve, nuclear translocation, c-FOS, Cyclin D1 | Different stimuli can induce different ERK dynamics; time points should be selected according to the model |
Is there feedback relief or drug resistance? | Time-course detection; combined RTK, AKT, and JNK/p38 indicators | p-RTK, p-AKT, p-MEK, p-ERK, p-JNK, p-p38 | If upstream RTKs or AKT increase after MEK/ERK inhibition, compensatory activation may be present |
Three points should be noted.
① Interpretation of RAF inhibitors must consider the genetic background. In BRAF V600E-driven models, BRAF inhibitors often effectively reduce MEK–ERK signaling. However, in RAS-activated or certain RAF dimerization contexts, some RAF inhibitors may produce complex effects and may even induce paradoxical ERK activation.
② A decrease in p-ERK after MEK inhibition only indicates that ERK activation depends on MEK; it does not automatically mean that all phenotypes are mediated by ERK.
③ KRAS G12C inhibitors apply only to KRAS G12C-mutant models. For KRAS G12D, G12V, or NRAS-mutant models, corresponding models and validation strategies should be selected, and G12C inhibitor logic should not be applied directly.
11. Representative Chemicals Related to MAPK/ERK Signaling Pathway Research
Table 1. Upstream Stimulation, Receptor Input, and Membrane-Proximal Signal Regulation
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
Protein kinase C pathway activator | 16561-29-8 | Phorbol 12-myristate 13-acetate, PMA | Moligand™, ≥98% | Used for protein kinase C activation, RAF–MEK–ERK pathway induction, cell differentiation models, and inflammatory response models | |
Epidermal growth factor receptor inhibitor | 184475-35-2 | Gefitinib, ZD1839 | Moligand™, ≥99% | Used for epidermal growth factor receptor signaling blockade, ERK phosphorylation detection, tumor cell proliferation, and drug sensitivity research | |
Epidermal growth factor receptor inhibitor | 183319-69-9 | Erlotinib hydrochloride, OSI-744 | Moligand™, ≥99% | Used for inhibition of epidermal growth factor receptor-dependent MEK–ERK signaling, lung cancer-related models, and targeted drug response research | |
Epidermal growth factor receptor inhibitor | 183321-74-6 | Erlotinib | Moligand™, ≥98% | Used for validation of epidermal growth factor receptor input, detection of decreased ERK phosphorylation, and cell proliferation experiments | |
Mutant epidermal growth factor receptor inhibitor | 1421373-65-0 | Osimertinib, AZD9291 | Moligand™, ≥99% | Used in epidermal growth factor receptor mutant models, ERK and AKT output detection, resistance mechanism studies, and combination drug research | |
Epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor | 231277-92-2 | Lapatinib | Moligand™, ≥99% | Used for dual-target inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2 input, ERK signaling, and proliferation phenotype analysis | |
BCR-ABL/PDGFR/c-Kit inhibitor | 220127-57-1 | Imatinib mesylate | ≥99% | Used for MAPK/ERK input studies related to platelet-derived growth factor receptor, c-Kit, and BCR-ABL | |
MET/ALK/ROS1 inhibitor | 877399-52-5 | Crizotinib | ≥99% | Used for MET- or ALK-driven ERK activation, receptor-dependence validation, and tumor cell proliferation research | |
Src family and RIP2 kinase inhibitor | 172889-27-9 | PP2, Src and RIP2 kinase inhibitor | Moligand™, ≥98% | Used for Src-mediated receptor transactivation, adhesion signal input, upstream ERK regulation, and migration models | |
Focal adhesion kinase inhibitor | 869288-64-2 | PF-573228, FAK inhibitor | ≥98% | Used for integrin–focal adhesion kinase signaling, cell adhesion and migration, and upstream ERK input analysis | |
Tyrosine phosphatase inhibitor | 13721-39-6 | Sodium orthovanadate | ≥99% | Used for maintaining tyrosine phosphorylation status, receptor phosphorylation detection, and MAPK/ERK sample processing |
Table 2. RAS Mutation, SOS1–KRAS Interaction, and RAS Membrane Localization Regulation
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
KRAS G12D inhibitor | 2621928-55-8 | MRTX1133 | Moligand™, ≥99% | Used in KRAS G12D-mutant models, RAS-dependent ERK output, tumor cell growth, and drug response research | |
KRAS G12C inhibitor | 2326521-71-3 | Adagrasib, MRTX849 | Moligand™, ≥98% | Used in KRAS G12C-mutant models, MAPK/ERK pathway inhibition, targeted drug sensitivity, and resistance research | |
KRAS G12C inhibitor | 2296729-00-3 | Sotorasib, AMG510 | Moligand™, ≥98% | Used for KRAS G12C mutation-dependent ERK signaling, cell proliferation inhibition, and drug combination research | |
SOS1–KRAS interaction inhibitor | 2230836-55-0 | BI-3406 | Moligand™, ≥98% | Used to inhibit SOS1-mediated KRAS activation, RAS-GTP formation, and downstream ERK output research | |
KRAS switch-region binding inhibitor | 2375482-51-0 | BI-2852 | ≥98% | Used for KRAS switch-region binding, RAS function regulation, and RAF–MEK–ERK signaling output analysis | |
RAS membrane localization disruptor | 162520-00-5 | Salirasib/FTS, Ras membrane localization disruptor | Moligand™, ≥98% | Used to disrupt the plasma membrane localization of activated Ras, weaken RAS-dependent RAF–MEK–ERK activation, and support tumor model research | |
Farnesyltransferase inhibitor | 192185-72-1 | Tipifarnib | Moligand™, ≥98% | Used for protein farnesylation intervention, HRAS membrane localization, ERK signaling, and tumor cell proliferation research | |
Farnesyltransferase inhibitor | 193275-84-2 | Lonafarnib | Moligand™, ≥95% | Used for protein farnesylation regulation, RAS membrane localization-related mechanisms, and MAPK/ERK output research | |
Farnesyltransferase-related inhibitor | 52665-74-4 | Manumycin A | ≥96% | Used for farnesyltransferase-related intervention, RAS membrane localization regulation, and ERK pathway-dependence validation |
Table 3. RAF-Level Inhibitors and RAF–MEK Signal Regulation
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
BRAF inhibitor | 1269440-17-6 | Encorafenib, LGX818 | Moligand™, ≥99% | Used in BRAF-mutant models, MEK–ERK output inhibition, melanoma, and colorectal cancer-related research | |
BRAF inhibitor | 918505-84-7 | PLX-4720, B-Raf inhibitor | Moligand™, ≥99% | Used in BRAF V600E-related models, MEK and ERK phosphorylation detection, and tumor cell proliferation research | |
BRAF inhibitor | 918504-65-1 | Vemurafenib, PLX4032, RG7204 | Moligand™, ≥98% | Used for inhibition of BRAF V600E-driven MAPK/ERK signaling, targeted drug response, and resistance mechanism research | |
BRAF inhibitor | 1195765-45-7 | Dabrafenib | Moligand™, ≥98% | Used in BRAF-mutant models, MEK/ERK downstream output analysis, and combined inhibition research | |
BRAF kinase inhibitor | 405554-55-4 | SB590885, B-Raf kinase inhibitor | ≥98% | Used for BRAF kinase activity inhibition, RAF–MEK–ERK cascade studies, and cell proliferation experiments | |
Pan-RAF inhibitor | 878739-06-1 | AZ 628, a novel pan-Raf inhibitor for BRAF, BRAF V600E, and c-Raf | Moligand™, ≥98% | Used for BRAF, BRAF V600E, and CRAF-related signal regulation, RAF dimers, and ERK reactivation research | |
Multi-target RAF-related inhibitor | 284461-73-0 | Sorafenib | Moligand™, ≥99% | Used for RAF-related signaling, angiogenic receptor signaling, tumor proliferation, and multi-target drug response research | |
Multi-target RAF-related inhibitor salt form | 475207-59-1 | Sorafenib tosylate | ≥99% | Used for inhibition of RAF- and angiogenic receptor-related pathways, tumor cell signal output, and pharmacodynamic evaluation |
Table 4. MEK1/2 and ERK1/2 Core Cascade Inhibitors
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
MEK1/2 inhibitor | 391210-10-9 | PD0325901, MEK1/2 inhibitor | Moligand™, ≥99% | Used to block MEK-mediated ERK phosphorylation, detect ERK downstream substrates, and study proliferation phenotypes | |
MEK1/2 inhibitor | 606143-52-6 | Selumetinib, AZD6244 | Moligand™, ≥99% | Used in RAS- or RAF-driven models, MEK–ERK pathway inhibition, and cell-cycle output analysis | |
MEK inhibitor | 305350-87-2 | SL-327, MEK inhibitor | Moligand™, ≥98%, mixture of isomers | Used for MEK/ERK signal blockade, nervous system ERK activation, and learning, memory, and synaptic plasticity-related models | |
MEK pathway inhibitor | 167869-21-8 | 2-(2-Amino-3-methoxyphenyl)chromone | Moligand™, ≥98% | Used for MEK activation blockade, ERK phosphorylation change detection, and MAPK pathway-dependence experiments | |
MEK1/2 inhibitor | 212631-79-3 | PD184352, CI-1040 | Moligand™, ≥98% | Used for MEK1/2 inhibition, ERK phosphorylation blockade, and MAPK pathway-dependence analysis | |
MEK inhibitor | 109511-58-2 | U0126, MKK inhibitor | Moligand™, ≥98% | Used to inhibit MKK/MEK-mediated ERK activation, detect ERK downstream substrates, and validate functional phenotypes | |
MEK inhibitor | 1173097-76-1 | U0126-EtOH, inhibitor | ≥97% | Used for MEK–ERK pathway blockade, ERK phosphorylation downregulation, and cell proliferation and differentiation models | |
MEK1/2 inhibitor | 871700-17-3 | Trametinib, GSK1120212 | Moligand™, ≥98% | Used for MEK1/2 inhibition, BRAF- or RAS-driven ERK output, and combination drug research | |
MEK inhibitor | 934660-93-2 | Cobimetinib | Moligand™, ≥98% | Used for MEK signal inhibition, BRAF inhibitor combination models, and tumor cell proliferation analysis | |
MEK inhibitor | 606143-89-9 | Binimetinib | Moligand™, ≥98% | Used for MEK–ERK cascade inhibition, RAF/RAS-driven models, and resistance mechanism research | |
ERK1/2 inhibitor | 869886-67-9 | Ulixertinib, BVD-523 | Moligand™, ≥99% | Used for ERK1/2 activity inhibition, ERK reactivation models after RAF or MEK inhibition, and downstream substrate detection | |
ERK inhibitor | 865362-74-9 | FR 180204, ERK inhibitor | Moligand™, ≥98% HPLC | Used for ERK kinase activity inhibition, ERK substrate phosphorylation detection, and cellular functional validation | |
ERK1/2 inhibitor | 942183-80-4 | SCH772984 | Moligand™, ≥98% | Used for ERK1/2 activity regulation, downstream output analysis such as RSK and ELK1, and MAPK pathway reactivation research | |
ERK2 inhibitor | 896720-20-0 | VX-11e, ERK2 inhibitor | Moligand™, ≥98% | Used for ERK2-dependent substrate phosphorylation, cell-cycle studies, and tumor cell proliferation research | |
ERK inhibitor | 1453848-26-4 | Ravoxertinib, ERK inhibitor | Moligand™, ≥97% | Used for ERK signaling output inhibition, MAPK pathway reactivation, and targeted drug combination research |
Table 5. ERK Downstream Effector Modules: RSK, MNK, and Transcriptional Output
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
RSK inhibitor | 501437-28-1 | BI-D1870 | Moligand™, ≥98% | Used for ERK–RSK axis inhibition, translation regulation, cell growth, and survival-related substrate analysis | |
RSK inhibitor | 1627709-94-7 | LJI308, RSK inhibitor | ≥98% HPLC | Used for RSK activity inhibition, ERK downstream signaling output, and tumor cell functional research | |
RSK inhibitor | 77307-50-7 | SL 0101-1, ribosomal S6 kinase, RSK, inhibitor | ≥95% HPLC | Used for ribosomal S6 kinase inhibition, ERK–RSK substrate validation, and cell proliferation research | |
MNK inhibitor | 522629-08-9 | CGP 57380, MNK inhibitor | Moligand™, ≥98% | Used for MNK-mediated translation regulation, eIF4E phosphorylation, and ERK/p38 downstream output research | |
MNK1/2 inhibitor | 1849590-01-7 | Tomivosertib, eFT-508 | Moligand™, ≥97% | Used for MNK1/2 inhibition, translation initiation regulation, and tumor- and immune-related signaling research | |
AP-1 transcriptional regulation inhibitor | 530141-72-1 | T-5224 | ≥97% | Used for AP-1-related transcriptional output, c-Fos/c-Jun regulation, and ERK downstream gene expression research |
Table 6. Parallel Pathways, MAPK Branches, and Mechanistic Control Tools
Category | CAS No. | Aladdin Cat. No. | Name | Specification or purity | Product features and applications |
p38 MAPK inhibitor | 152121-47-6 | SB-203580, p38 MAPK inhibitor | Moligand™, ≥98% HPLC | Used to distinguish ERK from the p38 stress branch, inflammatory factor expression, and cellular stress response research | |
PI3K inhibitor | 154447-36-6 | 2-Morpholino-8-phenylchromone | Moligand™, ≥98% | Used for PI3K–AKT parallel pathway inhibition, receptor downstream signal distinction, and cell survival analysis | |
AKT inhibitor | 1032350-13-2 | MK-2206 2HCl | Moligand™, ≥98% | Used for AKT signal inhibition, comparison of ERK and AKT parallel outputs, and cell survival and metabolism research | |
PI3K inhibitor | 19545-26-7 | Wortmannin | Moligand™, ≥98% | Used for PI3K pathway inhibition, AKT phosphorylation detection, and validation of receptor downstream parallel signaling | |
JNK inhibitor | 129-56-6 | Anthra[1,9-cd]pyrazol-6(2H)-one | Moligand™, ≥98% | Used for inhibition of the JNK stress branch, AP-1 activation, apoptosis, and inflammation-related signal distinction |
Note: The above are representative Aladdin products related to scientific research and formulation research. For more product specifications, grades, and COA information, search by “product name/CAS/Cat. No.” on the Aladdin website.
References
[1] Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–183.
[2] Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66(2):105–143.
[3] Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281–298.
[4] Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50–83.
[5] Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26(22):3227–3239.
[6] Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401–1409.
[7] Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290.
[8] Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80(2):179–185.
[9] Aoki K, Kumagai Y, Sakurai A, Komatsu N, Fujita Y, Shionyu C, Matsuda M. Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. Mol Cell. 2013;52(4):529–540.
[10] Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet. 2013;14:355–369.
For more related articles, see below:
Noncanonical Functions of Epigenetic Enzymes and Regulation of Mitochondrial Metabolism
Transposase-Based Epigenomic Sequencing Strategies: Principles and Recent Progress of CUT&Tag
Regulatory Framework and Biological Effects of the GSK3 Signaling Pathway
RANK Signaling Pathway: Molecular Components, Activation Mechanisms, and Biological Effects
CTLA4 Signaling Pathway: Molecular Basis, Immunoregulatory Mechanisms, and Disease Associations
Molecular Mechanisms and Biological Functions of the Fas Pathway
Type Stratification, Signal Transduction, and Effector Networks of the Interferon (IFN) Pathway
Wnt/β-Catenin Signaling Pathway
危险品化学品经营许可证（带存储）